Navigation Links
Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
Date:9/2/2010

Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010 -- LAUSANNE, Switzerland, September 2, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Awards Click to view news release full screen  

Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010

   

One of the Most Creative Researchers of his Generation in Pharmaceutical Technology

LAUSANNE, Switzerland, September 2, 2010 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today announced that the 'Debiopharm Life Sciences Award 2010' went to Professor Jean-Christophe Leroux for his innovative research on polymer chemistry, nanotechnology and pharmaceutical sciences to yield novel drug therapies. This year, the theme for the Award was "Drug Delivery and Pharmaceutical Technology". Professor Leroux is an expert in galenic studies from the Swiss Federal Institute of Technology (ETH) in Zurich. He and his institute received CHF 100'000. Funded by Debiopharm, the ceremony took place at the EPFL (Ecole Polytechnique Federale de Lausanne) during the EPFL School of Life Sciences Symposium entitled "Engineering Life".

"We congratulate Professor Leroux for his outstanding research," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group(TM). "A panel of experts from Debiopharm and the EPFL examined many high-level and promising applications from all over Europe; our decision to nominate Professor Leroux was unanimous. We were seduced by his innovative research, his general expertise and broad overall knowledge in drug delivery. The application file submitted by Professor Leroux was very comprehensive, with an impressive list of publications in high-impact factor pharmaceutical, materials and biomedical journals. He is a leading figure in an area that is likely to revolutionise medical therapeutics in the years to come."

The development of suitable drug formulations and delivery systems remains a major challenge in the full drug product development and industrialisation process. In his applied research, Professor Leroux is interested in the design of new carriers and materials for various pharmaceutical applications such as drug detoxification and the treatment of celiac disease (intolerance to gluten). Currently different approaches are being assessed as a supportive treatment of celiac disease. The polymeric binder technology which was developed in his laboratory will be further investigated. In parallel, he will examine another known strategy to study the stability of enzymes (exogenous propyl endopeptidases) in the gastro intestinal tract and try to improve it with various new polymers. He will also elaborate imaging tools to study in real time the enzymatic activity in vivo. Professor Leroux's more fundamental research aims to better understand how antisense oligonucleotides (ONs) and small interfering ribonucleic acids (siRNAs) are naturally taken up by cells and to discover ways by which he may enhance this phenomenon. The identification and exploitation of these uptake mechanisms have the potential to change our way of thinking about delivery of siRNAs and to provide basis for developing novel strategies for medicines based on RNA interference.

In 1992, Professor Leroux earned his B.Pharm from Montreal University and in 1995, his Ph.D. from Geneva University. He has held various positions at the Faculty of Pharmacy at Montreal University, from Assistant Professor to Adjunct Professor. Since 2008, Prof. Leroux has headed the laboratory of Drug Formulation and Delivery at the Institute of Pharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH) Zurich. He is among the major experts on liposomes and nanotechnologies in medicine.

About Debiopharm Group(TM)

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group has recently embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group(TM), please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact Maurice Wagner Director Corporate Affairs & Communication Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 mwagner@debiopharm.com Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 bhudspith@maitland.co.uk In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel: +1-212-845-4292 Fax: +1-212-845-4260 martina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Professor-turned-producer learns the movie biz
2. UCF professor develops vaccine to protect against black plague bioterror attack
3. Stuart Parkin first distinguished professor at Eindhoven University of Technology
4. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
5. UCF professor develops vaccine to protect against black plague bioterror attack
6. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
7. Gift Aids Professor's Research into Vein Treatment
8. Thin films research lands engineering professor Air Force Young Investigator Award
9. Nyenrode Honorary Doctorate for Professor Michael E. Porter
10. Professor K. C. Nicolaou Speaks at WuXi AppTec
11. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes, Jr. Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive ... Chief Commercial Officer with GenePeeks. Matt is a veteran life sciences and ... computational genomics company focused on identifying inherited disease risk in future generations. In ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health (Diameter) ... Health technology in the hands of Lantana analysts. The high-performance platform of Diameter ... public health entities – all those mining value from clinical data – to ...
Breaking Biology Technology:
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
Breaking Biology News(10 mins):